COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current e...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrati, Chiara, Di Cosimo, Serena, Fenoglio, Daniela, Apolone, Giovanni, Ciceri, Fabio, Ciliberto, Gennaro, Baldanti, Fausto, Costantini, Massimo, Giannarelli, Diana, Ippolito, Giuseppe, Locatelli, Franco, Mantovani, Alberto, Morrone, Aldo, Tagliavini, Fabrizio, Uccelli, Antonio, Zinzani, Pier Luigi, Silvestris, Nicola, Rescigno, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383886/
https://www.ncbi.nlm.nih.gov/pubmed/34447374
http://dx.doi.org/10.3389/fimmu.2021.704110

Ejemplares similares

Ejemplares similares